Parallax Volatility Advisers
HRTX icon

Parallax Volatility Advisers’s Heron Therapeutics HRTX Stock Holding History

Parallax Volatility Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-66,800
Closed -$1.63M – 3302
2015
Q3 		$1.63M Buy
+66,800
New +$2.23M ﹤0.01% 1107

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Parallax Volatility Advisers's HRTX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Heron Therapeutics (HRTX) in Q1 2018, closing a stake of 6,888 shares — an estimated $125K sold.

Parallax Volatility Advisers first reported a position in HRTX in Q4 2015 and held it in 8 quarters. The position peaked at $125K in Q4 2017. 152 funds tracked by Wall St. Rank hold HRTX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Heron Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 6,888 Heron Therapeutics shares in Q1 2018, an estimated $125K.
  • Parallax Volatility Advisers first reported a position in Heron Therapeutics in Q4 2015 and held it in 8 quarters.
  • Parallax Volatility Advisers's Heron Therapeutics position peaked at $125K in Q4 2017.
  • 152 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.